STOCK TITAN
  1. Home
  2. Sec-filings
  3. BIIB
  4. [Form 4] BIOGEN INC. Insider Trading Activity

[Form 4] BIOGEN INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Sean Godbout, identified as a Director and the issuer's Chief Accounting Officer, reported changes in his beneficial ownership of BioGen Inc. (BIIB) on 10/02/2025. He had restricted stock units (RSUs) vest that resulted in an acquisition of 502.6667 shares at no cash cost (code M), and on the same date he disposed of 8 shares by sale at $155.25 (code F), leaving him with 494.6667 shares reported as beneficially owned. The RSUs were granted on 10/02/2023 and vest in three equal annual installments beginning one year after the grant date; the filing was signed by an attorney-in-fact on 10/06/2025.

Sean Godbout, identificato come Direttore e Chief Accounting Officer dell'emittente, ha riportato cambiamenti nella proprietà beneficiante di BioGen Inc. (BIIB) in data 10/02/2025. I RSU (unità di azioni vincolate) hanno maturato per l'acquisizione di 502.6667 azioni a costo nullo (codice M); nello stesso giorno ha venduto 8 azioni per $155.25 (codice F), lasciando 494.6667 azioni come proprietà beneficiaria. Le RSU sono state concesse il 10/02/2023 e vestono in tre rate annuali uguali a partire da un anno dalla data di concessione; la dichiarazione è stata firmata da un procuratore in data 10/06/2025.

Sean Godbout, identificado como Director y el Chief Accounting Officer de la entidad emisora, reportó cambios en su propiedad beneficiosa de BioGen Inc. (BIIB) en la fecha 10/02/2025. Tenía unidades de acciones restringidas (RSUs) que se consolidaron, lo que dio lugar a la adquisición de 502.6667 acciones sin costo alguno (código M); en la misma fecha vendió 8 acciones por $155.25 (código F), quedando 494.6667 acciones reportadas como propiedad beneficiosa. Las RSU fueron otorgadas el 10/02/2023 y se consolidan en tres entregas anuales iguales a partir de un año después de la fecha de concesión; la declaración fue firmada por un apoderado el 10/06/2025.

Sean Godbout는 Director로 식별되며 발행사의 Chief Accounting Officer로서 BioGen Inc. (BIIB)의 실질적 소유 지분의 변경을 2025/02/10에 보고했습니다. 제한 주식 단위(RSUs)가 vesting되어 502.6667주를 현금 없이 취득했고(코드 M), 같은 날 8주를 매도하여 $155.25에 처분했습니다(코드 F). 그 결과 494.6667주가 실질적으로 소유로 보고되었습니다. RSU는 2023/02/10에 부여되어 부여일로부터 1년 후 시작해 매년 동일한 금액으로 세 차례 vesting되며, 보고서는 2025/10/06에 법정 대리인이 서명했습니다.

Sean Godbout, identifié comme Directeur et Chief Accounting Officer de l'émetteur, a signalé des changements dans sa propriété bénéficiaire de BioGen Inc. (BIIB) à la date 10/02/2025. Il détenait des unités d’actions restreintes (RSUs) qui se sont acquises, entraînant l’acquisition de 502,6667 actions sans coût en espèces (code M); le même jour, il a vendu 8 actions pour $155.25 (code F), le laissant avec 494,6667 actions déclarées comme détenues bénéficiaires. Les RSU ont été accordées le 10/02/2023 et vestent en trois versements annuels égaux à partir d’un an après la date de concession; le document a été signé par un mandataire le 10/06/2025.

Sean Godbout, identifiziert als Director und Chief Accounting Officer des Emittenten, meldete Änderungen an seinem begünstigten Eigentum von BioGen Inc. (BIIB) am 10/02/2025. Er hatte Restricted Stock Units (RSUs), die vesteten und zu einem Erwerb von 502,6667 Aktien ohne Barzahlung führten (Code M); am selben Tag veräußerte er 8 Aktien zu $155.25 (Code F), sodass er 494,6667 Aktien als begünstigt anerkannt behält. Die RSUs wurden am 10/02/2023 gewährt und vesten in drei gleichen jährlichen Teilbeträgen, beginnend ein Jahr nach dem Gewährungsdatum; die Einreichung wurde von einem Bevollmächtigten am 10/06/2025 unterschrieben.

Sean Godbout، مُعرّف كـ مدير وChief Accounting Officer للجهة المصدِرة، أبلغ عن تغييرات في ملكيته المستفيدة لـ BioGen Inc. (BIIB) في تاريخ 10/02/2025. كانت لديه وحدات الأسهم المقيدة (RSUs) التي تحققت من خلال الاستحقاق، مما أدى إلى اكتساب 502.6667 سهمًا دون مقابل نقدي (الرمز M)، وفي التاريخ نفسه باع 8 أسهم بـ $155.25 (الرمز F)، ليبقى لديه 494.6667 سهمًا موضحًا كملك beneficiary. تم منح RSUs في 10/02/2023 وتستحق مع ثلاثة أقسام سنوية متساوية ابتداءً من العام التالي لليونتي، كما أن التقرير تم توقيعه من قِبل وكيل قانوني في 10/06/2025.

Sean Godbout，被认定为董事及发行人的首席会计官，在2025-10-02报告了对BioGen Inc. (BIIB)的受益所有权变动。其拥有的受限股票单位（RSUs）已经归属，导致无现金取得了502.6667股（代码M）；同日又以$155.25的价格出售了8股（代码F），使其报告的受益所有权余额为494.6667股。RSUs于2023-10-02授予，并在授予日期一年后开始分三期按等额年度分 vesting；该申报书由一位代理人于2025-10-06签署。

Positive
  • RSU vesting converted to 502.6667 shares at no cash cost, reflecting compensation realization
  • Disclosure filed and signed (via attorney-in-fact), showing timely reporting of insider activity
Negative
  • Sale of 8 shares at $155.25 reduced holdings to 494.6667 shares

Insights

TL;DR: Officer reported RSU vesting and a small sale on 10/02/2025.

The reporting shows a non-cash vesting event of restricted stock units converting into 502.6667 shares (transaction code M), consistent with scheduled vesting rather than a market purchase. A contemporaneous sale of 8 shares at $155.25 (code F) reduced the post-transaction holdings to 494.6667 shares.

These entries align with routine compensation vesting and a minor disposition; compliance considerations include whether the sale complied with any pre-established trading plan. Monitor any future Form 4s for additional sales or large off-cycle dispositions within the next 12 months.

Sean Godbout, identificato come Direttore e Chief Accounting Officer dell'emittente, ha riportato cambiamenti nella proprietà beneficiante di BioGen Inc. (BIIB) in data 10/02/2025. I RSU (unità di azioni vincolate) hanno maturato per l'acquisizione di 502.6667 azioni a costo nullo (codice M); nello stesso giorno ha venduto 8 azioni per $155.25 (codice F), lasciando 494.6667 azioni come proprietà beneficiaria. Le RSU sono state concesse il 10/02/2023 e vestono in tre rate annuali uguali a partire da un anno dalla data di concessione; la dichiarazione è stata firmata da un procuratore in data 10/06/2025.

Sean Godbout, identificado como Director y el Chief Accounting Officer de la entidad emisora, reportó cambios en su propiedad beneficiosa de BioGen Inc. (BIIB) en la fecha 10/02/2025. Tenía unidades de acciones restringidas (RSUs) que se consolidaron, lo que dio lugar a la adquisición de 502.6667 acciones sin costo alguno (código M); en la misma fecha vendió 8 acciones por $155.25 (código F), quedando 494.6667 acciones reportadas como propiedad beneficiosa. Las RSU fueron otorgadas el 10/02/2023 y se consolidan en tres entregas anuales iguales a partir de un año después de la fecha de concesión; la declaración fue firmada por un apoderado el 10/06/2025.

Sean Godbout는 Director로 식별되며 발행사의 Chief Accounting Officer로서 BioGen Inc. (BIIB)의 실질적 소유 지분의 변경을 2025/02/10에 보고했습니다. 제한 주식 단위(RSUs)가 vesting되어 502.6667주를 현금 없이 취득했고(코드 M), 같은 날 8주를 매도하여 $155.25에 처분했습니다(코드 F). 그 결과 494.6667주가 실질적으로 소유로 보고되었습니다. RSU는 2023/02/10에 부여되어 부여일로부터 1년 후 시작해 매년 동일한 금액으로 세 차례 vesting되며, 보고서는 2025/10/06에 법정 대리인이 서명했습니다.

Sean Godbout, identifié comme Directeur et Chief Accounting Officer de l'émetteur, a signalé des changements dans sa propriété bénéficiaire de BioGen Inc. (BIIB) à la date 10/02/2025. Il détenait des unités d’actions restreintes (RSUs) qui se sont acquises, entraînant l’acquisition de 502,6667 actions sans coût en espèces (code M); le même jour, il a vendu 8 actions pour $155.25 (code F), le laissant avec 494,6667 actions déclarées comme détenues bénéficiaires. Les RSU ont été accordées le 10/02/2023 et vestent en trois versements annuels égaux à partir d’un an après la date de concession; le document a été signé par un mandataire le 10/06/2025.

Sean Godbout, identifiziert als Director und Chief Accounting Officer des Emittenten, meldete Änderungen an seinem begünstigten Eigentum von BioGen Inc. (BIIB) am 10/02/2025. Er hatte Restricted Stock Units (RSUs), die vesteten und zu einem Erwerb von 502,6667 Aktien ohne Barzahlung führten (Code M); am selben Tag veräußerte er 8 Aktien zu $155.25 (Code F), sodass er 494,6667 Aktien als begünstigt anerkannt behält. Die RSUs wurden am 10/02/2023 gewährt und vesten in drei gleichen jährlichen Teilbeträgen, beginnend ein Jahr nach dem Gewährungsdatum; die Einreichung wurde von einem Bevollmächtigten am 10/06/2025 unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Godbout Sean
(Last) (First) (Middle)
225 BINNEY
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Accounting Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/02/2025 M 26 A $0 502.6667 D
Common Stock 10/02/2025 F 8 D $155.25 494.6667 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit $0 10/02/2025 M 26 (1) 10/02/2026 Common Stock 26 $0 27 D
Explanation of Responses:
1. The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 10/02/2023.
/s/ Wendell Taylor, attorney-in-fact for Mr. Godbout 10/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did the BIIB Form 4 filed by Sean Godbout report?

The form reports vesting of 502.6667 RSU-derived shares and a sale of 8 shares at $155.25 on 10/02/2025, leaving 494.6667 shares beneficially owned.

What is the nature of the securities that vested for BIIB insider Sean Godbout?

The vested securities were restricted stock units (RSUs) granted on 10/02/2023 that vest in three equal annual installments starting one year after the grant date.

How many shares does Sean Godbout beneficially own after the reported transactions?

After the reported transactions on 10/02/2025, he beneficially owns 494.6667 shares.

At what price were the sold shares transacted?

The sale recorded on 10/02/2025 lists a disposal of 8 shares at $155.25.

Who signed the Form 4 for Sean Godbout and when?

The Form 4 was signed by Wendell Taylor, attorney-in-fact for Mr. Godbout on 10/06/2025.
Stock BIIB logo
Biogen Inc

NASDAQ:BIIB

BIIB Rankings

#538 Ranked by Market Cap
N/A Ranked by Dividends

BIIB Latest News

BIIB Latest SEC Filings

BIIB Stock Data

23.44B
146.36M
0.15%
92.56%
3.22%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE